Development of spiropyran Based Metal Complexes as Potent Drug Candidate for Effective Photodynamic and Photothermal Cancer Therapy
Implementing Organization
Ymca University Of Science & Technology
Principal Investigator
Dr. Bhawna Uttam
Ymca University Of Science & Technology
CO-Principal Investigator
Dr. Amit Rajput
Ymca University Of Science & Technology
About
Cancer is a leading cause of death globally, with 8.4 million deaths and 14 million new patients each year. In India, the cancer population is estimated at 13.9 lakhs this year, and it is predicted to increase to 15.9 lakhs by the end of 2025. To address this challenge, new methodologies are needed, including gene therapy, immunotherapy, photodynamic, and photothermal therapy. Photodynamic therapy (PDT) uses photosensitizers to treat malignant tissue, generating toxic reactive oxygen species (ROs) that cause irreversible cellular damage. Photothermal therapy (PTT) uses PTT agents to destroy tumors by interacting with external lasers. There is still a need for enhancement of both therapies, and combining PTT/PDT therapy could introduce more advancements in cancer treatment. Near-infrared (NIR) light is a convenient light source due to its high tissue penetration ability. Organic photothermal agents, such as diarylethenes and spiropyrans, can fulfill the critical requirements for photothermal therapy, such as strong absorption in the NIR region, quick degradation after use, easy synthesis and modification, and nontoxicity in the absence of photoirridation. Photochromic spiropyran (sP) molecules have been explored as drug candidates for PTT/PDT therapy. Objectives include designing spiropyran-based photo-switchable ligands, synthesizing photoswitchable spiropyrane-based metal complexes, characterizing, photoelectrochemical, and calirimetric studies, and assessing the anticancer activity of photoswitichable spiropyran derivatives.
Source
Source
Anusandhan National Research Foundation/science and Engineering Research Board (sERB), DsT 2023-24
Science and Engineering Research Board (SERB), New Delhi
Anusandhan National Research Foundation (ANRF)
Quick Information
Area of Research
Pharmaceutical Sciences
Start Year
2023
End Year
2026
Sanction Amount
₹ 22.94 L
Status
Ongoing
Contact
bhawnauttam@jcboseust.ac.in
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
00
No. of Patents
Filed :00
Grant :00
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.